Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

20040019.LumA

— · A

bf60f00c-5d92-55e1-9a2c-28033708820c

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
A
subtype
A

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
  • UV_RESPONSE_DN+0.400
  • PANCREAS_BETA_CELLS+0.370
  • INTERFERON_ALPHA_RESPONSE+0.360
  • KRAS_SIGNALING_UP+0.350
  • ALLOGRAFT_REJECTION+0.340
  • COAGULATION+0.330
  • COMPLEMENT+0.290
  • INTERFERON_GAMMA_RESPONSE+0.290
  • INFLAMMATORY_RESPONSE+0.280

Top 10 suppressed

  • MYC_TARGETS_V2-0.780
  • E2F_TARGETS-0.670
  • MYC_TARGETS_V1-0.630
  • G2M_CHECKPOINT-0.600
  • MTORC1_SIGNALING-0.560
  • OXIDATIVE_PHOSPHORYLATION-0.500
  • UNFOLDED_PROTEIN_RESPONSE-0.490
  • DNA_REPAIR-0.450
  • GLYCOLYSIS-0.400
  • MITOTIC_SPINDLE-0.310

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-55-8621-01A-11R-2403-07
lung-landscapes@6
—cohortA10.931
2TCGA-AC-A2FF-01A-11R-A17B-07
breast-umap@18
—A0.922
3TCGA-S2-AA1A-01A-12R-A39D-07
lung-landscapes@6
—cohortA10.920
4TCGA-98-A53C-01A-11R-A262-07
lung-landscapes@6
—cohortMD20.917
5SRR26320092
bladder-landscape@3
——0.916
6SRR8518299
breast-umap@18
—A0.916
7SRR8518405
breast-umap@18
—A0.915
844eb0b78-9761-4131-b831-85e765a24e6b
colon-landscapes@1
——0.910
9TCGA-L4-A4E6-01A-11R-A24H-07
lung-landscapes@6
—cohortA10.910
1059f108c6-677f-4cf2-89fd-6bd15133dd6f
colon-landscapes@1
——0.909

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 23 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.400Inavolisib— uncovered
UV_RESPONSE_DN0.400Inavolisib— uncovered
PANCREAS_BETA_CELLS0.370Cobimetinib— uncovered
INTERFERON_ALPHA_RESPONSE0.360Inavolisib— uncovered
KRAS_SIGNALING_UP0.350Inavolisib— uncovered
ALLOGRAFT_REJECTION0.340Idelalisib— uncovered
COAGULATION0.330Binimetinib— uncovered
COMPLEMENT0.290Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.290Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.280Idelalisib— uncovered
ANGIOGENESIS0.260Remibrutinib— uncovered
HEDGEHOG_SIGNALING0.260Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.260Inavolisib— uncovered
MYOGENESIS0.210Inavolisib— uncovered
APICAL_JUNCTION0.160Inavolisib— uncovered
IL2_STAT5_SIGNALING0.160Idelalisib— uncovered
TGF_BETA_SIGNALING0.150Inavolisib— uncovered
APICAL_SURFACE0.100Temsirolimus— uncovered
XENOBIOTIC_METABOLISM0.090Inavolisib— uncovered
BILE_ACID_METABOLISM0.070Inavolisib— uncovered